Actively Recruiting
Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients
Led by Mỹ Đức Hospital · Updated on 2026-03-20
222
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized clinical trial aims to assess the comparative effectiveness of two distinct endometrial preparation protocols for frozen embryo transfer (FET) among women with adenomyosis undergoing IVF/ICSI. Specifically, it seeks to address the following key questions: 1. Does the protocol involving the combination of GnRH agonist and letrozole for down regulation with exogenous steroids (GnRHa+AI - AC) result in a higher live birth rate compared to the use of exogenous steroids alone (AC) in women with adenomyosis undergoing frozen embryo transfer? 2. What are the common side effects of the GnRHa+AI - AC regimen? Eligible participants will undergo screening before endometrial preparation for FET, following which they will be randomly assigned to one of two groups: GnRHa+AI - AC or AC. In the GnRHa+AI - AC group, participants will be pre-treated with GnRH agonist and letrozole two months before endometrial preparation. After this period, participants will return for endometrial preparation, and any side effects resulting from the down regulation will be evaluated. In contrast, the AC group will receive standard treatment.
CONDITIONS
Official Title
Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed adenomyosis diagnosis by transvaginal ultrasonography or pelvic MRI
- Age between 18 and 42 years
- Have undergone three or fewer previous IVF cycles
- Scheduled for frozen embryo transfer
- Agree to transfer no more than two day-3 embryos or one blastocyst (day-5 or day-6)
- Not participating in any other clinical study
You will not qualify if you...
- Embryos from in vitro maturation (IVM) cycles
- Uterine or adnexal abnormalities such as intrauterine adhesions, unicornuate, bicornuate, arcuate uterus, unremoved hydrosalpinx, endometrial polyp, submucosal leiomyoma, or leiomyoma distorting the endometrial cavity
- Contraindications to hormone treatment including breast cancer or risk of venous thromboembolism
- Embryos from oocyte donation cycles
- History of GnRH injections within three months prior to screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
My Duc Hospital
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 70000
Actively Recruiting
Research Team
T
Tien K Le, MD
CONTACT
V
Vu NA Ho, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here